Temporally distinct cognitive effects following acute administration of ketamine and phencyclidine in the rat

European Neuropsychopharmacology

Volumn 23, Issue 11, 2013, Pages 1414-1422

  Gastambide, Francois ^a   Mitchell, Stephen N ^a   Robbins, Trevor W ^b   Tricklebank, Mark D ^a   Gilmour, Gary ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Attention; Executive control; Motor; NMDA; Pharmacokinetics; Schizophrenia

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENTION; BRAIN TISSUE; COGNITION; DRUG EFFECT; LEARNING; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; RESPONSE TIME; TASK PERFORMANCE;

ATTENTION; EXECUTIVE CONTROL; MOTOR; NMDA; NMDAR; NON-COMPETITIVE N-METHYL-D-ASPARTATE RECEPTOR; PCP; PHARMACOKINETICS; PHENCYCLIDINE; SCHIZOPHRENIA; SIMPLE REACTION TIME; SRT; VARIABLE INTERVAL; VI;

ANIMALS; COGNITION; CONDITIONING, OPERANT; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MALE; PHENCYCLIDINE; RATS; REACTION TIME; REINFORCEMENT SCHEDULE; TIME FACTORS;

EID: 84886769409     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.03.002     Document Type: Article

References (42)

1. Absalom A.R., Lee M., Menon D.K., Sharar S.R., De S.T., Halliday J., Ogden M., Corlett P., Honey G.D., Fletcher P.C. Predictive performance of the Domino, Hijazi, and Clements models during low-dose target-controlled ketamine infusions in healthy volunteers. Br. J. Anaesth. 2007, 98:615-623.
2. Adams B., Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci. 1998, 18:5545-5554.
3. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., Breier A. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry 1999, 156:1646-1649.
4. Amitai N., Markou A. Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-d-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia. Biol. Psychiatry 2010, 68:5-16.
5. Andrews J.S. Possible confounding influence of strain, age and gender on cognitive performance in rats. Brain Res.: Cognit. Brain Res. 1996, 3:251-267.
6. Barch D.M., Dowd E.C. Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophr. Bull. 2010, 36:919-934.
7. Buckner R.L., Andrews-Hanna J.R., Schacter D.L. The brain's default network: anatomy, function, and relevance to disease. Ann. N. Y. Acad. Sci. 2008, 1124:1-38.
8. Dalley J.W., Mar A.C., Economidou D., Robbins T.W. Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry. Pharmacol. Biochem. Behav. 2008, 90:250-260.
9. Dalmau J., Lancaster E., Martinez-Hernandez E., Rosenfeld M.R., Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011, 10:63-74.
10. Dix S., Gilmour G., Potts S., Smith J.W., Tricklebank M. A within-subject cognitive battery in the rat: differential effects of NMDA receptor antagonists. Psychopharmacology (Berl.) 2010, 212:227-242.
11. Evenden J.L. Varieties of impulsivity. Psychopharmacology (Berl.) 1999, 146:348-361.
12. Fletcher P.C., Honey G.D. Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits. Trends Cognit. Sci. 2006, 10:167-174.
13. Foussias G., Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr. Bull. 2010, 36:359-369.
14. Franken I.H., van Strien J.W., Nijs I., Muris P. Impulsivity is associated with behavioral decision-making deficits. Psychiatry Res. 2008, 158:155-163.
15. Gastambide F., Cotel M.C., Gilmour G., O'Neill M.J., Robbins T.W., Tricklebank M.D. Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator. Neuropsychopharmacology 2012, 37:1057-1066.
16. Gastambide F., Gilmour G., Robbins T.W., Tricklebank M.D. The mGlu5 positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat. Neuropharmacology 2013, 64:240-247.
17. Gilmour G., Dix S., Fellini L., Gastambide F., Plath N., Steckler T., Talpos J., Tricklebank M. NMDA receptors, cognition and schizophrenia-testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 2012, 62:1401-1412.
18. Gilmour G., Pioli E.Y., Dix S.L., Smith J.W., Conway M.W., Jones W.T., Loomis S., Mason R., Shahabi S., Tricklebank M.D. Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia. Psychopharmacology (Berl.) 2009, 205:203-216.
19. Heckers S., Tandon R., Bustillo J. Catatonia in the DSM-shall we move or not?. Schizophr. Bull. 2010, 36:205-207.
20. Irani S.R., Bera K., Waters P., Zuliani L., Maxwell S., Zandi M.S., Friese M.A., Galea I., Kullmann D.M., Beeson D., Lang B., Bien C.G., Vincent A. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010, 133:1655-1667.
21. Izquierdo A., Jentsch J.D. Reversal learning as a measure of impulsive and compulsive behavior in addictions. Psychopharmacology (Berl.) 2012, 219:607-620.
22. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
23. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32:214-219.
24. Kos T., Nikiforuk A., Rafa D., Popik P. The effects of NMDA receptor antagonists on attentional set-shifting task performance in mice. Psychopharmacology (Berl.) 2011, 214:911-921.
25. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
26. Krystal J.H., Perry E.B., Gueorguieva R., Belger A., Madonick S.H., Abi-Dargham A., Cooper T.B., Macdougall L., Abi-Saab W., D'Souza D.C. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch. Gen. Psychiatry 2005, 62:985-994.
27. Leeson V.C., Robbins T.W., Matheson E., Hutton S.B., Ron M.A., Barnes T.R., Joyce E.M. Discrimination learning, reversal, and set-shifting in first-episode schizophrenia: stability over six years and specific associations with medication type and disorganization syndrome. Biol. Psychiatry 2009, 66:586-593.
28. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117:697-706.
29. Lu H., Zou Q., Gu H., Raichle M.E., Stein E.A., Yang Y. Rat brains also have a default mode network. Proc. Natl. Acad. Sci. USA 2012, 109:3979-3984.
30. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996, 14:301-307.
31. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17:141-150.
32. Messinger J.W., Tremeau F., Antonius D., Mendelsohn E., Prudent V., Stanford A.D., Malaspina D. Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin. Psychol. Rev. 2011, 31:161-168.
33. Morrens M., Hulstijn W., Sabbe B. Psychomotor slowing in schizophrenia. Schizophr. Bull. 2007, 33:1038-1053.
34. Nikiforuk A., Golembiowska K., Popik P. Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats. Eur. Neuropsychopharmacol. 2010, 20:37-48.
35. Pattij T., Vanderschuren L.J. The neuropharmacology of impulsive behaviour. Trends Pharmacol. Sci. 2008, 29:192-199.
36. Pomarol-Clotet E., Honey G.D., Murray G.K., Corlett P.R., Absalom A.R., Lee M., McKenna P.J., Bullmore E.T., Fletcher P.C. Psychological effects of ketamine in healthy volunteers. Phenomenological study. Br. J. Psychiatry 2006, 189:173-179.
37. Rowland L.M., Astur R.S., Jung R.E., Bustillo J.R., Lauriello J., Yeo R.A. Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology 2005, 30:633-639.
38. Smith J.W., Gastambide F., Gilmour G., Dix S., Foss J., Lloyd K., Malik N., Tricklebank M. A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology (Berl.) 2011, 217:255-269.
39. Thomson D.M., McVie A., Morris B.J., Pratt J.A. Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine. Psychopharmacology (Berl.) 2011, 213:681-695.
40. Walther S., Strik W. Motor symptoms and schizophrenia. Neuropsychobiology 2012, 66:77-92.
41. Williamson P. Are anticorrelated networks in the brain relevant to schizophrenia?. Schizophr. Bull. 2007, 33:994-1003.
42. Zandi M.S., Irani S.R., Lang B., Waters P., Jones P.B., McKenna P., Coles A.J., Vincent A., Lennox B.R. Disease-relevant autoantibodies in first episode schizophrenia. J. Neurol. 2011, 258:686-688.